Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31697314 | 0.85 | KDM4E (0.50) | KDM4EALDH1A1TSHRNPSR1CA12 | |
| SCHEMBL1498542 | 0.85 | KDM4E (0.50) | KDM4EALDH1A1TSHRNPSR1CA12 | |
| SCHEMBL24834467 | 0.84 | KDM4E (0.48) | KDM4EALDH1A1TSHRNPSR1CA12 | |
| SCHEMBL4192553 | 0.84 | KDM4E (0.58) | KDM4EALDH1A1TSHRNPSR1CA12 | |
| SCHEMBL29827383 | 0.84 | KDM4E (0.48) | KDM4EALDH1A1TSHRNPSR1CASP1 | |
| SCHEMBL28944494 | 0.84 | KDM4E (0.48) | KDM4EALDH1A1TSHRNPSR1CASP1 | |
| SCHEMBL2435522 | 0.83 | TUBB4A (0.56) | KDM4ETSHRMAPTTUBB4ATUBB | |
| SCHEMBL30480593 | 0.83 | TUBB4A (0.56) | KDM4ETSHRMAPTTUBB4ATUBB | |
| SCHEMBL2098039 | 0.83 | KDM4E (0.45) | KDM4EALDH1A1TSHRNPSR1CASP1 | |
| SCHEMBL6216482 | 0.82 | KDM4E (0.47) | KDM4EALDH1A1TSHRNPSR1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163446-A | Quinoline ketone skeleton PDE4 inhibitor and preparation method and application thereof | 中山大学 | 2022-03-11 | — | — | CN | claimed |
| US-20250382296-A1 | NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| EP-4655293-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | Syngenta Crop Protection AG (CH) | 2025-12-03 | — | — | EP | disclosed |
| EP-4567036-A1 | NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| WO-2024156664-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA CROP PROTECTION AG (CH) | 2024-08-02 | — | — | WO | disclosed |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3687543-B1 | COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2015131031-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015000715-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2015-01-08 | — | — | WO | disclosed |
| US-20130045963-A1 | Cyclohexyl Azetidine Derivatives as JAK Inhibitors | INCYTE CORPORATION (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045963-A1 | Cyclohexyl Azetidine Derivatives as JAK Inhibitors | INCYTE CORPORATION (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2013026025-A1 | CYCLOHEXYL AZETIDINE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013026025-A1 | CYCLOHEXYL AZETIDINE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2013-02-21 | — | — | WO | disclosed |
| US-20130045963-A1 | Cyclohexyl Azetidine Derivatives as JAK Inhibitors | INCYTE CORPORATION (US) | 2013-02-21 | — | — | US | disclosed |
| US-5250548-A | Treating hypertension, heart failure | ABBOTT LABORATORIES (US) | 1993-10-05 | — | — | US | disclosed |
| US-5118680-A | COMBATING ENDOPARASITES WITH 3-HYDROXYBENZOTHIOPHENES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-06-02 | — | — | US | disclosed |
| EP-0403885-A1 | Utilization of 3-hydroxybenzothiophens for combatting endoparasites, new 3-hydroxythiophens and process for their preparation | BAYER AG (DE) | 1990-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382296-A1 | NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | PRMT5, PRMT1, PRMT8 | KDM4E 134/4885ALDH1A1 4401/4885TSHR 3940/4885 |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | KDM4E 1198/4885ALDH1A1 621/4885TSHR 1396/4885 |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | KDM4E 1198/4885ALDH1A1 621/4885TSHR 1396/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | KDM4E 1198/4885ALDH1A1 621/4885TSHR 1396/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | KDM4E 4059/4885ALDH1A1 4172/4885TSHR 4229/4885 |
| US-20130045963-A1 | Cyclohexyl Azetidine Derivatives as JAK Inhibitors | JAK1, JAK2, JAK3 | KDM4E 162/4885ALDH1A1 2907/4885TSHR 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.